Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Top Cited Papers
Open Access
- 3 April 2020
- Vol. 9 (4), 875
- https://doi.org/10.3390/cells9040875
Abstract
Liver fibrosis due to viral or metabolic chronic liver diseases is a major challenge of global health. Correlating with liver disease progression, fibrosis is a key factor for liver disease outcome and risk of hepatocellular carcinoma (HCC). Despite different mechanism of primary liver injury and disease-specific cell responses, the progression of fibrotic liver disease follows shared patterns across the main liver disease etiologies. Scientific discoveries within the last decade have transformed the understanding of the mechanisms of liver fibrosis. Removal or elimination of the causative agent such as control or cure of viral infection has shown that liver fibrosis is reversible. However, reversal often occurs too slowly or too infrequent to avoid life-threatening complications particularly in advanced fibrosis. Thus, there is a huge unmet medical need for anti-fibrotic therapies to prevent liver disease progression and HCC development. However, while many anti-fibrotic candidate agents have shown robust effects in experimental animal models, their anti-fibrotic effects in clinical trials have been limited or absent. Thus, no approved therapy exists for liver fibrosis. In this review we summarize cellular drivers and molecular mechanisms of fibrogenesis in chronic liver diseases and discuss their impact for the development of urgently needed anti-fibrotic therapies.Keywords
Funding Information
- European Union (ERC-AdG-2014-HEPCIR #671231, EU H2020-HEPCAR #667273, ERC PoC-HEPCAN #862551)
- Deutsche Forschungsgemeinschaft (RO 5983/1-1)
- French National Research Agency (PLAN CANCER 2014-2019 HCCMICTAR, LABEX ANR-10-LABX-0028-HEPSYS)
This publication has 390 references indexed in Scilit:
- SIRT1 Is Required for AMPK Activation and the Beneficial Effects of Resveratrol on Mitochondrial FunctionCell Metabolism, 2012
- Mechanisms of hepatic fibrogenesisBest Practice & Research Clinical Gastroenterology, 2011
- The nicotinamide adenine dinucleotide phosphate oxidase (NOX) homologues NOX1 and NOX2/gp91phox mediate hepatic fibrosis in miceJournal of Hepatology, 2011
- Bone Marrow-Derived Myofibroblasts Contribute to the Mesenchymal Stem Cell Niche and Promote Tumor GrowthCancer Cell, 2011
- Lineage tracing demonstrates no evidence of cholangiocyte epithelial-to-mesenchymal transition in murine models of hepatic fibrosisJournal of Hepatology, 2011
- β-Catenin Regulates Mesenchymal Progenitor Cell Differentiation During HepatogenesisJournal of Surgical Research, 2010
- Hepatocytes do not undergo epithelial-mesenchymal transition in liver fibrosis in miceJournal of Hepatology, 2009
- CCR2 promotes hepatic fibrosis in miceJournal of Hepatology, 2009
- Immune Interactions in Hepatic FibrosisClinics in Liver Disease, 2008
- Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory responseJournal of Hepatology, 2008